Published November, 2010
By Gary J. Kelloff, Ernest T. Hawk and Caroline C. Sigman
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

---

Published November, 2010
By Hak Choy
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Internationally recognized experts in cancer biology and clinical research review the present status of the multimodality approach to the management of solid tumors and speculate on possible future strategies for chemoradiation therapy. A review of how to integrate new specific molecular targeted agents into multimodality therapy in the future.

---

Published November, 2010
By Moulay A. Alaoui-Jamali and Lawrence C. Panasci
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

A comprehensive review of the recent developments in DNA repair that have potential for translational and clinical applications.

---

Published November, 2010
By Antonio Giordano and Kenneth J. Soprano
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Leading clinicians and investigators review in a comprehensible and user-friendly style all the latest information about the molecular biology of cell cycle control and demonstrate its clinical relevance to understanding neoplastic diseases.

---

Published November, 2010
By Wei Dai
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Checkpoint Responses in Cancer Therapy summarizes the advances made over the past 20 years, identifying components of cell-cycle checkpoints and their molecular regulation during checkpoint activation and validating the use of checkpoint proteins as targets for the development of anticancer drugs.

---

Published September, 2010
By Rebecca G. Bagley
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

The fact that tumors are composed of both tumor cells and host cells has long been known. These tumor-associated cells include vascular endothelial cells and pe- cytes, as well as inflammatory cells such as neutrophils, monocytes, macrophages, mast cells and eosinophils, and lymphocytes.

---

Published August, 2010
By Vitaly A. Polunovsky, Peter J. Houghton and Vitaly Polunovsky
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island).

---

Published June, 2010
By Benjamin Bonavida
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

This monograph will be the first to focus on studies that investigate the role of NO in tumor cell pathogenesis, growth, angiogenesis, response to cytotoxic therapies and NO translational applications in cancer therapy, alone or in conjunction with other therapies.

---

Published November, 2009
By L. Harivardhan Reddy and Patrick Couvreur
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

This book details the macromolecular therapeutics for cancer therapy. It also covers the classification of these anticancer drugs based on therapeutic targets and elaborates on different classes of anticancer therapeutics.

---

Published September, 2009
By V. Craig Jordan, B.J.A. Furr and JORDAN V. CRAIG
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

This book describes the principles underlying targeted hormonal treatments, assesses the actions of new and established agents, and illustrates the new applications of hormonal chemoprevention for breast cancer.

---